ERBB2 and breast cancer: Given the overexpression ofendothelial growth factor receptor or HER2 in some HR + BC, it has been suggested that EGFR‐ and HER2‐targeting agents could be a potential treatment strategy.84, 85 The phase III trial Cancer and Leukaemia Group B 40302B (CALGB 40302/Alliance) study (NCT00390455) investigated the combination of the dual EGFR‐HER2 inhibitor lapatinib with fulvestrant compared with lapatinib alone in women with advanced HR+/HER2− or HER2 + BC that was resistant to endocrine therapy.